Compare GSIT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSIT | ACIU |
|---|---|---|
| Founded | 1995 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | GSIT | ACIU |
|---|---|---|
| Price | $7.32 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.8M | 418.4K |
| Earning Date | 01-29-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,024,000.00 | $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.00 | N/A |
| 52 Week Low | $1.62 | $1.43 |
| 52 Week High | $18.15 | $4.00 |
| Indicator | GSIT | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 49.89 |
| Support Level | $7.10 | $3.24 |
| Resistance Level | $8.05 | $3.90 |
| Average True Range (ATR) | 0.91 | 0.25 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 18.26 | 24.24 |
GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia. In addition, it serves the ongoing needs of the military, aerospace, industrial, test and measurement equipment, and automotive and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and the United States.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.